hERG channel-expressing cell

Details hERG channel-expressing cell hERG channel-expressing cell

2011-05-03

2011-05-03

Pak, Michael (Department: 1646)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Reexamination Certificate

active

07935526

ABSTRACT:
It is an object of the present invention to establish a method of establishing a cell with a remarkably high hERG channel expression level for use in predicting adverse effects based on hERG channel inhibition in research and development of drugs, and to thereby establish a highly sensitive and high throughput evaluation method.By inserting a hERG gene into a retrovirus vector plasmid or lentivirus vector plasmid to thereby prepare a virus vector, concentrating the vector by ultracentrifugation if necessary, transferring the hERG gene into cells and expressing hERG channels therein, it has become possible to secure an expression level effective in measurements using a fully automated high throughput patch clamp system or dyes.

REFERENCES:
patent: 5512421 (1996-04-01), Burns et al.
patent: WO-02/19966 (2002-03-01), None
patent: WO-03/027634 (2003-04-01), None
“High Throughput Ion-Channel Pharmacology: Planar-Array-Based Voltage Clamp” by Kiss et al., Assay and Drug Development Technologies, vol. 1, No. 1-2, 2003, pp. 127-135.
Nuss, H. B., et al, Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes, The Journal of Clinical Investigation, Mar. 1999, vol. 103, No. 6, p. 889-896.
Hoppe, U. C., et al., Distinct gene-specific mechanism of arrhythmia revealed by cardiac gene transfer of two long QT disease genes,HERGandKCNE1, PNAS, Apr. 24, 2001, vol. 98, No. 9, p. 5335-5340.
Pfohl, J. L., et al., Society for Neuroscience Abstracts, 2001, vol. 27, No. 2, p. 2149.
Morgenstern, J. P. et al. “Advanced mammalian gene transfer: high titre retrovirla vectors with multiple drug selection markers and a complementary helper-free packaging cell line.” Nucleic Acids Research, Oxford University Press, Surrey GB, vol. 19, No. 12, 1990, p. 3587-3596.
“ViraPowerTM Lentiviral Expression System.” 2002, Invitrogen Corporation. (http://www.invitrogen.com/content/sfs/brochures/710—021387—viralPowerAnnounc.pdf).
Schroeder, Kirk S. “An interview with Kirk S. Schroeder, President, Essen Instruments.” Assay and Drug Development Technologies. Nov. 2002, vol. 1, No. 1, pt 1. Nov. 2002 pp. 3-8.
Bennett, P. B. et al. “Trends in Ion-Channel Drug Discovery: Advances in Screening Technologies.” Trends in Biotechnology, Elsevier Publications, Cambridge, GB, vol. 21, No. 12. Oct. 28, 2003 (pp. 563-569).
Dull et al., “A Third-Generation Lentivirus Vector with a Conditional Packaging System”, J. of Virology, 72(11):8463-8471(1998).
Pearlstein et al., “Characterization of HERG Potassium Channel Inhibition Using CoMSiA 3D QSAR and Homology Modeling Approaches”, Bioorganic & Medicinal Chemistry Letters 13:1829-1835 (2003).
Schroeder et al., “IonWorks™ HT: A New High-Throughput Electrophysiology Measurement Platform”, Journal of Biomolecular Screening 8(1):50-64 (2003).
Japanese Office Action for Application No. 2005-515507, dated Mar. 2, 2010 (with English translation) 9 pages.
Japanese Office Action for Application No. 2005-515507, dated Jun. 8, 2010 (with English translation) 9 pages.

Affiliated with

Also associated with

Rating

hERG channel-expressing cell does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with hERG channel-expressing cell, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and hERG channel-expressing cell will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2671475